Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial


Author: Ting Bao1, Raymond Baser2, Connie Chen3, Matthew Weitzman1, Yi Lily Zhang1, Christina Seluzicki1, Qing Susan Li1, Lauren Piulson1, W Iris Zhi4

Affiliation: <sup>1</sup> Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.

<sup>2</sup> Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY, 10017, USA.

<sup>3</sup> Department of Medicine, NYU Winthrop Hospital, 259 1st St, Mineola, NY, 11501, USA.

<sup>4</sup> Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 650 Commack Road, Commack, NY, 11725, USA.
Conference/Journal: Oncologist
Date published: 2021 Aug 14
Other:
  Special Notes: doi: 10.1002/onco.13933.   ,  Word Count: 365  
    Background:

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating adverse effect of neurotoxic chemotherapy that significantly worsens cancer survivors' quality of life.



Materials and methods:

Solid tumor survivors with persistent moderate-to-severe CIPN defined as numbness, tingling, or pain rated ≥4 on an 11-point numeric rating scale (NRS) were randomized in a 1:1:1 ratio to eight weeks of real acupuncture (RA) versus sham acupuncture (SA) versus usual care (UC). We previously reported the primary endpoint (NRS); here we report health-related quality of life endpoints: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), and Brief Fatigue Inventory (BFI). For each endpoint, the mean changes from baseline and 95% confidence intervals were estimated within each arm and compared between arms using linear mixed models.



Results:

We enrolled 75 solid tumor survivors with moderate to severe CIPN into the study. Compared to baseline, at week 8, FACT/GOG-Ntx, HADS anxiety, and ISI scores significantly improved in RA and SA, but not in UC. Compared to UC, at week 8, FACT/GOG-Ntx scores significantly increased in RA and SA arms indicating improved CIPN-related symptoms and quality of life (p=0.001 and p=0.01). There was no statistically significant difference between RA and SA. There was no difference in HADS depression or BFI among RA, SA, and UC at weeks 8 and 12.



Conclusion:

Acupuncture may improve CIPN-related symptoms and quality of life in cancer survivors with persistent CIPN. Further large sample size studies are needed to delineate placebo effects.



Trial registration:

ClinicalTrials.gov (NCT03183037) IMPLICATIONS FOR PRACTICE: We conducted a randomized sham acupuncture- and usual care-controlled clinical trial to evaluate the impact of acupuncture on health-related quality of life outcomes in solid tumor patients with chemotherapy-induced peripheral neuropathy (CIPN). Statistically significant improvements in quality of life, anxiety, insomnia, and fatigue were achieved with eight weeks of real acupuncture when compared to baseline, without statistically significant differences between real and sham acupuncture. These findings suggest that acupuncture may be effective for improving CIPN-related symptoms and quality of life and reducing anxiety and insomnia in cancer survivors with persistent CIPN, with further study needed to delineate placebo effects.



Keywords: acupuncture; anxiety; cancer; insomnia; neuropathy; quality of life.



PMID: 34390283 DOI: 10.1002/onco.13933